Table 8.

Male Pubertal Assays: Frequency of Endpoint Alterations

	Study data: statistically altered endpoint (0 = not altered; 1 = altered)
Endpoint	Aa	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	Statistically altered endpoint (%)
Body wtb/gain (prepuberty)c	0	1	0	0	1	1	1	0	0	0	0	1	0	1	0	0	0	0	0	0	0	29
Body wt/gain (termination)	0	0	0	0	1	1	1	0	0	0	0	1	0	1	0	0	0	0	0	0	0	24
Absolute age at preputial separation (PPS)	0	0	0	0	0	1	1	0	1	0	0	0	0	1	0	0	0	0	0	0	0	19
Adjusted age at PPS	1	0	0	1	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	19
Absolute body wt at PPS	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	10
Adjusted body weight at PPS	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	10
Relative liver wt	1	1	0	1	1	1	1	1	1	1	0	1	0	0	1	0	0	0	1	0	0	57
Relative kidney wt	0	0	0	0	0	0	0	0	1	1	0	1	0	1	1	0	0	0	1	0	0	29
Relative pituitary wt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Relative adrenal wt	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	10
Absolute ventral prostate wt	0	0	0	1	1	1	1	0	0	0	0	1	0	1	0	0	0	0	0	0	0	29
Adjusted ventral prostate wt	0	0	0	1	1	1	1	0	1	0	0	1	0	1	0	0	0	0	0	0	0	33
Absolute dorsolateral prostate wt	0	0	0	1	1	0	1	0	1	0	0	1	0	0	0	0	0	0	0	0	0	24
Adjusted dorsolateral prostate wt	0	1	0	1	1	0	1	0	1	0	0	1	0	0	0	0	0	0	0	0	0	29
Absolute wt SV w/CG with fluidd	1	0	0	1	1	1	1	0	0	0	0	1	0	1	0	0	0	0	0	0	0	33
Adjusted wt SV w/CG with fluid	1	0	0	1	1	0	1	0	1	0	0	1	0	1	0	0	0	0	0	0	0	33
Absolute wt SV w/CG without fluid	1	0	0	1	1	0	1	0	0	0	0	1	0	1	0	0	0	0	0	0	0	29
Adjusted wt SV w/CG without fluid	1	0	0	1	1	0	1	0	1	0	0	1	0	1	0	0	0	0	0	0	0	33
Absolute LABC wte	0	1	0	1	1	1	1	0	0	0	0	1	0	1	0	0	1	0	0	0	0	38
Adjusted LABC wt	0	1	0	1	1	1	1	0	0	0	0	1	0	1	0	0	1	0	0	0	0	38
Absolute right epididymis wt	0	1	0	0	1	0	1	0	0	0	0	1	0	1	0	0	0	0	1	0	0	29
Adjusted right epididymis wt	0	1	0	0	1	0	1	0	0	0	0	1	0	1	0	0	0	0	1	0	0	29
Absolute left epididymis wt	0	1	0	0	1	0	1	0	0	0	0	1	0	1	0	0	0	0	0	0	0	24
Adjusted left epididymis wt	0	1	0	0	1	0	1	0	0	0	0	1	0	1	0	0	0	0	0	0	0	24
Absolute right testis wt	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	10
Adjusted right testis wt	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	5
Absolute left testis wt	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
Adjusted left testis wt	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
Absolute thyroid wt	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	10
Adjusted thyroid wt	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	10
Blood urea nitrogen (BUN)	1	0	0	1	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	19
Creatinine	0	1	0	1	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	24
Serum T4 levels	0	1	0	0	1	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	19
Serum TSH levels	0	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	14
Serum T levels	1	0	0	1	1	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	1	29
Thyroid follicular cell height	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	10
Thyroid colloid amount	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	10
Thyroid histopathologyf	0	0	0	1	1	0	0	1	0	0	0	1	0	0	0	0	0	0	1	0	0	24
Testis histopathology	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Epididymis histopathology	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
Kidney histopathology	0	1	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	14

^aData in this table reflect the same studies referenced in Table 1, although the sequence has been changed.

^bwt, Weight.

^cBody weight/body weight gain during intervals leading up to PPS (e.g., PND 35–45).

1 = Statistically significant difference in treated group(s) compared with concurrent controls; 0 = no difference between treated and control groups.

^dSV w/CG, seminal vesicles with coagulating glands.

^eLABC, levator ani-bulbocavernosus muscles.

^fHistopathology results for thyroid, testis, epididymis, and kidney were qualitative; therefore, 1 = treatment-related difference and 0 = no difference from controls.